Videos
Articles
Biological Treatment of Chronic Rhinosinusitis With Polyps Increases Number of Nasal Ciliated Cells—Real-Life Experience
G. Stryjewska-Makuch, M. Humeniuk-Arasiewicz, M. Onyszczuk, et al. Allergy. First published: 10 July 2025
Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive
Y. Deng, N. Leib, S. Schnautz, et al. Allergy. First published: 09 July 2025
Transcriptomic Analysis of Allergic Patch Test Reactions in Non-Atopic Patients: A Comparative Study Across Multiple Allergens
D. Pesqué, E. Andrades, P. Berenguer-Molins, et al. Allergy. First published: 09 July 2025
Phytic Acid Improves the Skin Barrier Function in Murine Models of Atopic Dermatitis Through Skin Microbiota-Derived Indole-3-Propionic Acid
P. Wang, L. Yang, L. Chen, et al. Allergy. First published: 09 July 2025
Validation of the Skin Prick Automated Test (SPAT) Cut-Off Value in Birch Pollen and House Dust Mite Allergic Rhinitis Patients
S. F. Seys, A. Gherasim, F. Odul, et al. Allergy. First published: 09 July 2025
Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study
J. A. Layhadi, S. Starchenka, P.-J. De Kam, et al. Allergy. First published: 08 July 2025
Skin-Derived PGD2 Promotes Antigen-Specific IgE Production via CRTH2 Signaling
M. Kida, T. Nakamura, S. Maeda, et al. Allergy. First published: 03 July 2025
Algorithms in Allergy: Diagnosis and Treatment of Atopic Dermatitis Complicated by Eczema Herpeticum
S. Traidl, A. Heratizadeh, and T. Werfel. Allergy. First published: 02 July 2025
Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real-World Pooled Analysis
F. Schleich, S. Loukides, R. Chaudhuri, et al. Allergy. First published: 01 July 2025
Type 2 Immunity and Its Role in Allergic Disorders
Y.-d. Gao, Z.-j. Wang, I. Ogulur, et al. Allergy. First published: 30 June 2025
OX40 and Regulatory Marker Alterations in Lesional and Non-Lesional Keloid Tissues
J. Bar, E. David, E. Del Duca, et al. Allergy. First published: 27 June 2025
Effect of the Multi-Strain Probiotic SYN-53 in the Management of Allergic Rhinoconjunctivitis
K.-C. Bergmann and T. Zuberbier. Allergy. First published: 27 June 2025
Pre-Analytical Stability of Diagnostic Biomarkers in Primary Blood Tubes for Supporting Remote Allergy Care
J. Ruinemans-Koerts, Y. Schmidt-Hieltjes, H. de Waard, et al. Allergy. First published: 27 June 2025
CCR2-Dependent Monocyte Recruitment Accelerates Allergic Airway Inflammation in Diesel Exhaust-Exposed Mice
S. H. Seok, S. H. Han, M. R. Jeong, et al. Allergy. First published: 26 June 2025
Exploring the Diversity and Emerging Powers of Eosinophil Subpopulations
A. Ecrement, V. Spasovoski, G. Rolin, and C. Barnig. Allergy. First published: 26 June 2025
High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma
L. Wirth, W. Weigel, C. T. Stamper, et al. Allergy. First published: 26 June 2025
Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta-Analysis of Eight Retrospective Studies
F. Spataro, F. Cacciapaglia, P. Carlucci, et al. Allergy. First published: 25 June 2025
Sleep Disturbance Mediates the Association Between Disease Activity and Work Productivity Impairments in Chronic Urticaria
H. W. F. Mak, E. Lee, J. C. Y. Wong, and P. H. Li. Allergy. First published: 25 June 2025
Association of Atopic Dermatitis or Allergic Rhinitis With Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
D. K.-H. Lin and H.-C. Chang. Allergy. First published: 25 June 2025
Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study
J. Levine, R. K. Islam, L. Mo, et al. Allergy. First published: 25 June 2025
Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities
G. W. Canonica, C. Porsbjerg, D. B. Price et al. Allergy. First published: 23 June 2025
Deciphering Immune Endotypes Within Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
C. von Wachter, M. Ameri, T. Chimbetete, et al. Allergy. First published: 23 June 2025
Reply to Correspondence: ‘Challenging the Frontier: Bridging Systemic Biomarkers and Small Airway Dynamics in Severe Asthma Management’
Contreras, N., Delgado-Dolset, M.I., Villaseñor, A. and Escribese, M.M. Allergy. First published: 20 June 2025
Improved Transition Management of Adolescents and Young Adults With Allergy and/or Asthma: An EAACI Task Force Report on a Follow-Up European Survey
Atzert, N., Gore, C., Knibb, R.C., et al. Allergy. First published: 17 June 2025
Role for Complement C5 in Eosinophilic Inflammation of Severe Asthma
Dong, C., Lu, S., Deng, Z., et al. Allergy. First published: 16 June 2025
A Growing Concern for Cashew and an Unexpected Risk From Almonds: Data From the Anaphylaxis Registry
Höfer, V., Dölle-Bierke, S., Sabouraud-Leclerc, D., et al. Allergy. First published: 13 June 2025
Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper
Pascal, M., Chauhan, J., Knol, E., et al. Allergy. First published:12 June 2025
Patterns of Respiratory Symptoms and Asthma Diagnosis in School-Age Children: Three Birth Cohorts
Cucco, A., Simpson, A., Haider, S., et al. Allergy. First published: 12 June 2025
Uncontrolled Asthma, Intimate Partner Violence, and Inflammatory Pathways: Surprising Insights From Cytokine Profiles
Shibuya, K., Balasubramanyam, S., Verma, D., et al. Allergy. First published: 12 June 2025
Basal Serum Tryptase Outperforms Hereditary Alpha Tryptasemia as a Biomarker of Food Allergy Severity
Loli-Ausejo, D., Gonzalez-Matamala, M.F., Martí, D., et al. Allergy. First published: 12 June 2025
Strategies for Flow Cytometric Profiling of BCR IgH Isotypes: A Comparative Assessment of FcR Blocking Agents
Ardicli, O., Lopez, J.F., Starrenburg, M.E., et al. Allergy. First published: 12 June 2025
Disruption of the Vagal TRPA1-Pulmonary Neuroendocrine Cell Axis Reduces Asthma Severity
Feng, X., Xue, Y., Bao, R., et al. Allergy. First published: 10 June 2025
The Impact of Rhinovirus, Syncytial Respiratory Virus and Helminth Infection on the Risk of New-Onset Asthma and Other Allergic Conditions—A Systematic Review for the EAACI Guidelines on Environmental Science for Allergic Diseases and Asthma
Agache, I., Salazar, J., Rodriguez-Tanta, Y., et al. Allergy. First published: 10 June 2025
Keratinocyte-Derived Glucocorticoids Maintain Immune Balance During Transient Skin Barrier Perturbation
Phan, T.S., Lambrecht, R., Merk, V.M., et al. Allergy. First published: 05 June 2025
Genetically Determined Inflammation-Related Proteins in Asthma and Type-2 Signatures
Hernandez-Pacheco, N., Björkander, S., Merid, S.K., et al. Allergy. First published: 04 June 2025
Vulnerability to Pollen-Related Asthma Hospital Admissions in the UK Biobank: A Case-Crossover Study
et al. Allergy. First published: 03 June 2025
Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health-Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis
Ryser, F.S., Demeter, T., Pijuan, J.B., et al. Allergy. First published: 02 June 2025
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
The past few months have been incredibly busy for JMA representatives participating in various meetings!
From 27-29 March 2025, during the Skin Allergy Meeting (SAM 2025) in Bilbao, Spain, JMA representatives played an important role in the scientific organization of the event. They organized the Junior Member session, which focused on topics such as urticaria, mastocytosis, and atopic dermatitis. Throughout the meeting, Junior Members were highly engaged, particularly in oral and poster discussion sessions. SAM 2025 proved to be an excellent platform for sharing research and clinical expertise to improve care for patients with skin allergies.
In addition, JMA members gathered in the stunning region of Cappadocia, Turkey (10-12 April 2025), for the Allergy School in Allergen Immunotherapy. This event was a great success, with outstanding speakers and the active participation of our Junior Members in oral presentations, poster sessions, and workshops. Our JMA representatives played an essential role throughout the meeting.
Finally, two of our JMA representatives traveled to South Korea to attend the KAAACI Seoul International Congress 2025. There, they presented scientific contributions and took part in numerous networking events, including the “Young Investigator Night”, which fostered meaningful exchanges and new connections between young researchers from Asia and Europe. It was an unforgettable experience!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
